Abstract
Intra-uterine growth retardation (IUGR) represents one of the major problems in perinatal medicine. IUGR is one of main causes of perinatal mortality and morbidity. A huge number and variety of established and possible causes of IUGR have been described. There are currently no data about effective treatment of this fetal condition. IUGR has been described to be strictly involved in fetal programming. Fetal programming is the general idea, which tells us how during development of the embryo and fetus significant physiological parameters can be shaped by environmental events. A link between the intra-uterine growth retardation and the risk of developing type 2 diabetes, obesity and cardiovascular disease postnatally has been well documented. The aim of this paper is to present an overview of the current knowledge of IUGR effects on development of hypertension and cardiovascular diseases, impact on insulin secretion and resistance, diabetes mellitus and metabolic syndrome. The influence of intrauterine growth retardation on predisposition to obesity and adipose dysfunction was also described.
Keywords: Intra-uterine growth retardation, fetal programming, cardiovascular diseases, insulin secretion, insulin resistance, metabolic syndrome.
Current Pharmaceutical Biotechnology
Title:Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders
Volume: 17 Issue: 7
Author(s): Radzislaw Mierzynski, Dominik Dluski, Dorota Darmochwal-Kolarz, Elzbieta Poniedziałek-Czajkowska, Bozena Leszczynska-Gorzelak, Zaneta Kimber-Trojnar, Agnieszka-Wankowicz and Jan Oleszczuk
Affiliation:
Keywords: Intra-uterine growth retardation, fetal programming, cardiovascular diseases, insulin secretion, insulin resistance, metabolic syndrome.
Abstract: Intra-uterine growth retardation (IUGR) represents one of the major problems in perinatal medicine. IUGR is one of main causes of perinatal mortality and morbidity. A huge number and variety of established and possible causes of IUGR have been described. There are currently no data about effective treatment of this fetal condition. IUGR has been described to be strictly involved in fetal programming. Fetal programming is the general idea, which tells us how during development of the embryo and fetus significant physiological parameters can be shaped by environmental events. A link between the intra-uterine growth retardation and the risk of developing type 2 diabetes, obesity and cardiovascular disease postnatally has been well documented. The aim of this paper is to present an overview of the current knowledge of IUGR effects on development of hypertension and cardiovascular diseases, impact on insulin secretion and resistance, diabetes mellitus and metabolic syndrome. The influence of intrauterine growth retardation on predisposition to obesity and adipose dysfunction was also described.
Export Options
About this article
Cite this article as:
Mierzynski Radzislaw, Dluski Dominik, Darmochwal-Kolarz Dorota, Poniedziałek-Czajkowska Elzbieta, Leszczynska-Gorzelak Bozena, Kimber-Trojnar Zaneta, Agnieszka-Wankowicz and Oleszczuk Jan, Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders, Current Pharmaceutical Biotechnology 2016; 17 (7) . https://dx.doi.org/10.2174/1389201017666160301104323
DOI https://dx.doi.org/10.2174/1389201017666160301104323 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sleep Loss and Hypertension: A Systematic Review
Current Pharmaceutical Design Current Status of Complementary and Alternative Medicine in the Treatment of Rheumatic Disease Pain
Current Rheumatology Reviews Insights into Oxidative Stress: The Isoprostanes
Current Medicinal Chemistry Application of Aptamer-based Hybrid Molecules in Early Diagnosis and Treatment of Diabetes Mellitus: From the Concepts Towards the Future
Current Diabetes Reviews Socioeconomic Status: The Missing Link Between Obesity and Diabetes Mellitus?
Current Diabetes Reviews Gene Therapy for Pituitary Tumors
Current Gene Therapy Nanoparticles: Properties and Applications in Cancer Immunotherapy
Current Pharmaceutical Design Blood Pressure Control and Diabetic Retinopathy
Current Hypertension Reviews Far-infrared Ray-mediated Antioxidant Potentials are Important for Attenuating Psychotoxic Disorders
Current Neuropharmacology <i>In silico</i> Studies on the Interaction Between Bioactive Ligands and DPPIV: Insights on Potential Candidates for the Treatment of type 2 Diabetes Mellitus
Medicinal Chemistry 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Assessment of Glomerular and Tubular Function
Current Pediatric Reviews <i>Aloe vera</i>: An Unconventional Food Used to Reduce Hyperglycemia and Hyperlipidemia: Evidence from Pre-clinical and Clinical Studies
Current Nutrition & Food Science Anti-Diabetic Agents from Natural Products — An Update from 2004 to 2009
Current Topics in Medicinal Chemistry Antioxidant Activity of Plant Phenols: Chemical Mechanisms and Biological Significance
Current Organic Chemistry Diabetes of the Brain: Computational Approaches and Interventional Strategies
CNS & Neurological Disorders - Drug Targets Many Drugs and Phytochemicals Can Be Activated to Biological Reactive Intermediates
Current Drug Metabolism Invariant Natural Killer T Cell-Based Therapy of Autoimmune Diseases
Current Immunology Reviews (Discontinued) Type 2 Transglutaminase in Neurodegenerative Diseases: The Mitochondrial Connection
Current Pharmaceutical Design Buccoadhesive Dosage Form Containing Antifungal Agent for Treating Oropharyngeal Candidiasis: A Review
Current Drug Therapy